Medroxyprogesterone caproate information

Medroxyprogesterone caproate
Clinical data
Other names	MPC; Medroxyprogesterone capronate; Medroxyprogesterone hexanoate; 6α-Methyl-17α-hydroxyprogesterone hexanoate; 6α-Methyl-17α-hydroxypregn-4-ene-3,20-dione hexanoate
Routes of; administration	Intramuscular injection
Drug class	Progestogen; Progestin; Progestogen ester
Identifiers
	IUPAC name [(6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate;
CAS Number	6678-23-5;
PubChem CID	62997;
ChemSpider	56699;
UNII	GNC5BCM98A;
CompTox Dashboard (EPA)	DTXSID00216902 ;
Chemical and physical data
Formula	C28H42O4
Molar mass	442.640 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C)C)C(=O)C;
	InChI InChI=1S/C28H42O4/c1-6-7-8-9-25(31)32-28(19(3)29)15-12-23-21-16-18(2)24-17-20(30)10-13-26(24,4)22(21)11-14-27(23,28)5/h17-18,21-23H,6-16H2,1-5H3/t18-,21+,22-,23-,26+,27-,28-/m0/s1; Key:RDNJGIAWTAMGGM-UPIZIACDSA-N;

Medroxyprogesterone caproate (MPC) is a progestin and a progestogen ester which was synthesized in 1958 but was never marketed.^[1]^[2] It has been confused with hydroxyprogesterone caproate (OHPC) and medroxyprogesterone acetate (MPA) in a number of publications.^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12] In addition to MPA and OHPC, analogues of MPC include chlormadinone caproate, gestonorone caproate, megestrol caproate, and methenmadinone caproate.

^ Babcock JC, Gutsell ES, Herr ME, Hogg JA, Stucki JC, Barnes LE, Dulin WE (1958). "6α-Methyl-17α-hydroxyprogesterone 17-acylates; a new class of potent progestins". Journal of the American Chemical Society. 80 (11): 2904–2905. doi:10.1021/ja01544a079. ISSN 0002-7863.
^ Barton DH, Taylor WC (1958). "510. Photochemical transformations. Part IV. The photochemistry of prednisone acetate". Journal of the Chemical Society (Resumed): 2500–2510. doi:10.1039/jr9580002500. ISSN 0368-1769.
^ Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J (April 1998). "Progestins and breast cancer". The Journal of Steroid Biochemistry and Molecular Biology. 65 (1–6): 225–235. doi:10.1016/S0960-0760(98)00028-4. PMID 9699877. S2CID 28416130.
^ Pasqualini JR, Ebert C (June 1999). "Biological effects of progestins in breast cancer". Gynecological Endocrinology. 13 (Suppl 4): 11–19. doi:10.1080/gye.13.s4.11.19. PMID 12227897.
^ Pasqualini JR, Chetrite GS (December 2010). "Biological responses of progestogen metabolites in normal and cancerous human breast". Hormone Molecular Biology and Clinical Investigation. 3 (3): 427–435. doi:10.1515/HMBCI.2010.066. PMID 25961215. S2CID 41680565.
^ Lantta M, Kahanpää K, Kärkkäinen J, Lehtovirta P, Wahlström T, Widholm O (June 1984). "Estradiol and progesterone receptors in two cases of endometrial stromal sarcoma". Gynecologic Oncology. 18 (2): 233–239. doi:10.1016/0090-8258(84)90031-3. PMID 6735266.
^ Gusberg SB, Shingleton HM, Deppe G (1988). Female genital cancer. Churchill Livingstone. p. 374. ISBN 978-0-443-08525-3.
^ Proceedings. American Cancer Society and National Cancer Institute of the U.S. Public Health Service, Federal Security Agency. 1970. p. 376.
^ Nichols DH, Evrard JR (1985). Ambulatory Gynecology. Harper & Row. p. 518. ISBN 978-0-06-141815-0.
^ Goodman LS, Gilman A (1996). Goodman & Gilman's the Pharmacological Basis of Therapeutics. McGraw-Hill, Health Professions Division. pp. 1427, 1823, 1858. ISBN 978-0-07-026266-9.
^ Endokrinologie. Johann Ambrosius Barth Verlag. 1969. p. 431.
^ McKinnon AO, Tarrida Del Marmol Figueroa S, Nobelius AM, Hyland JH, Vasey JR (1993). "Failure of medroxyprogesterone caproate to maintain pregnancy in ovariectomised mares". Equine Vet J. 25 (2): 158–160. doi:10.1111/j.2042-3306.1993.tb02928.x. PMID 8467776.

[BabcockGutsell1958-1] Babcock JC, Gutsell ES, Herr ME, Hogg JA, Stucki JC, Barnes LE, Dulin WE (1958). "6α-Methyl-17α-hydroxyprogesterone 17-acylates; a new class of potent progestins". Journal of the American Chemical Society. 80 (11): 2904–2905. doi:10.1021/ja01544a079. ISSN 0002-7863.

[BartonTaylor1958-2] Barton DH, Taylor WC (1958). "510. Photochemical transformations. Part IV. The photochemistry of prednisone acetate". Journal of the Chemical Society (Resumed): 2500–2510. doi:10.1039/jr9580002500. ISSN 0368-1769.

[pmid9699877-3] Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J (April 1998). "Progestins and breast cancer". The Journal of Steroid Biochemistry and Molecular Biology. 65 (1–6): 225–235. doi:10.1016/S0960-0760(98)00028-4. PMID 9699877. S2CID 28416130.

[pmid12227897-4] Pasqualini JR, Ebert C (June 1999). "Biological effects of progestins in breast cancer". Gynecological Endocrinology. 13 (Suppl 4): 11–19. doi:10.1080/gye.13.s4.11.19. PMID 12227897.

[pmid25961215-5] Pasqualini JR, Chetrite GS (December 2010). "Biological responses of progestogen metabolites in normal and cancerous human breast". Hormone Molecular Biology and Clinical Investigation. 3 (3): 427–435. doi:10.1515/HMBCI.2010.066. PMID 25961215. S2CID 41680565.

[pmid6735266-6] Lantta M, Kahanpää K, Kärkkäinen J, Lehtovirta P, Wahlström T, Widholm O (June 1984). "Estradiol and progesterone receptors in two cases of endometrial stromal sarcoma". Gynecologic Oncology. 18 (2): 233–239. doi:10.1016/0090-8258(84)90031-3. PMID 6735266.

[GusbergShingleton1988-7] Gusberg SB, Shingleton HM, Deppe G (1988). Female genital cancer. Churchill Livingstone. p. 374. ISBN 978-0-443-08525-3.

[ACSNCI1970-8] Proceedings. American Cancer Society and National Cancer Institute of the U.S. Public Health Service, Federal Security Agency. 1970. p. 376.

[NicholsEvrard1985-9] Nichols DH, Evrard JR (1985). Ambulatory Gynecology. Harper & Row. p. 518. ISBN 978-0-06-141815-0.

[GoodmanGilman1996-10] Goodman LS, Gilman A (1996). Goodman & Gilman's the Pharmacological Basis of Therapeutics. McGraw-Hill, Health Professions Division. pp. 1427, 1823, 1858. ISBN 978-0-07-026266-9.

[JohannAmbrosiusBarthVerlag1969-11] Endokrinologie. Johann Ambrosius Barth Verlag. 1969. p. 431.

[NobeliusHyland1993-12] McKinnon AO, Tarrida Del Marmol Figueroa S, Nobelius AM, Hyland JH, Vasey JR (1993). "Failure of medroxyprogesterone caproate to maintain pregnancy in ovariectomised mares". Equine Vet J. 25 (2): 158–160. doi:10.1111/j.2042-3306.1993.tb02928.x. PMID 8467776.

Medroxyprogesterone caproate information

and 20 Related for: Medroxyprogesterone caproate information

Medroxyprogesterone caproate

Medroxyprogesterone

Hydroxyprogesterone caproate

Medroxyprogesterone acetate

Triamcinolone acetonide

List of progestogen esters

Megestrol caproate

Dydrogesterone

Methenmadinone caproate

Segesterone acetate

Spironolactone

Progestogen

Trenbolone acetate

Megestrol acetate

Trenbolone

Mometasone

Drospirenone

Steroid

Cyproterone acetate

Ulipristal acetate

Clinical data

Other names	MPC; Medroxyprogesterone capronate; Medroxyprogesterone hexanoate; 6α-Methyl-17α-hydroxyprogesterone hexanoate; 6α-Methyl-17α-hydroxypregn-4-ene-3,20-dione hexanoate
Routes of administration	Intramuscular injection
Drug class	Progestogen; Progestin; Progestogen ester
Identifiers
IUPAC name [(6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate
CAS Number	6678-23-5
PubChem CID	62997
ChemSpider	56699
UNII	GNC5BCM98A
CompTox Dashboard (EPA)	DTXSID00216902
Chemical and physical data
Formula	C₂₈H₄₂O₄
Molar mass	442.640 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C)C)C(=O)C
InChI InChI=1S/C28H42O4/c1-6-7-8-9-25(31)32-28(19(3)29)15-12-23-21-16-18(2)24-17-20(30)10-13-26(24,4)22(21)11-14-27(23,28)5/h17-18,21-23H,6-16H2,1-5H3/t18-,21+,22-,23-,26+,27-,28-/m0/s1 Key:RDNJGIAWTAMGGM-UPIZIACDSA-N